April 14, 2021
Business News

Uncertainty of Government Pricing Policies, Evolution of PBMs, and 340B Program Expansion Identified as Top External Challenges for Pharma Pricing & Contracting Teams This Year

WALTHAM, Mass.–()–Trinity Life Sciences, a leader in global life sciences commercialization solutions, is sharing findings from its latest TGaS annual Landscape report entitled, “2021 Trends & Considerations in Contract Management: Responding to Pricing Pressures in an Uncertain Environment.” The report, based on biopharma companies in varying stages of development, finds that uncertainty of government pricing policies, evolution of pharmacy benefit managers (PBMs) and 340B Program* expansion are the top challenges for contracting teams at biopharma companies this year.

“Trump’s Executive Orders, materialized in Most Favored Nation and Safe Harbor Rebate Protection removal final rules at the end of…

Click here to view the original article.

Related Posts

You might also like ...

The Hundred Club of Massachusetts Announces Affiliation with Home Base
Hedy Aguilera Joins DataLink as Vice President, Enterprise Project Management
AON Splash Image
GenScript Biotech BV and IES Diagnostics Forge Distribution Agreement for SARS-CoV-2 Neutralizing Antibody Kit